Avadel Pharmaceuticals plc (AVDL) Financial Analysis & Valuation | Quarter Chart
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company w... more
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead pr... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $2.12B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IE | CEO | Gregory J. Divis Jr. |
| IPO Date | 1996-06-07 | CAGR | 13.48% |
| Employees | 188 | Website | www.avadel.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AVDL chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $1.44B | P/E | -1082 | Forward P/E | — | PEG | — |
| P/S | 8.55 | P/B | 21.39 | P/CF | 59.03 | P/FCF | 59.99 |
| Sales | $248.52M | Sales 1Y | 79.88% | Sales 3Y | — | Sales 5Y | 645.65% |
| EPS | $-0.02 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | -99.9% |
| Sales QoQ | 13.71% | EPS QoQ | -99.8% | Sales QoQ Avg | 12.1% | EPS QoQ Avg | -83.28% |
| Gross Margin | 94.47% | Operating Margin | 1.82% | Profit Margin | -0.11% | ROCE | 3.3% |
| ROA | — | ROE | — | Altman Z Score | 9.06 | Piotroski Score | 4 |
| Current Ratio | 2.76 | Quick Ratio | 2.37 | Cash Ratio | 1.28 | Op. CF Ratio | 0.37 |
| Debt/Equity | 0.38 | Debt/Assets | 0.19 | Lt Debt/Equity | 0.37 | Lt Debt/Cap. | 0.26 |
| Intrst Cov. | 0.47 | Inventory Turnover | 0.58 | Asset Turnover | 1.25 | Receivables Turnover | 5.86 |
| Enterprise Value | $1.44B | P/E Ratio | -1082 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 8.55 | P/B Ratio | 21.39 |
| P/CF Ratio | 59.03 | P/FCF Ratio | 59.99 |
| EPS | $-0.02 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | -99.9% |
| Revenue Growth 1Y | 79.88% | Gross Margin | 94.47% |
| Operating Margin | 1.82% | Profit Margin | -0.11% |
| ROE | — | ROA | — |
| ROCE | 3.3% | Current Ratio | 2.76 |
| Quick Ratio | 2.37 | Cash Ratio | 1.28 |
| Debt/Equity | 0.38 | Interest Coverage | 0.47 |
| Altman Z Score | 9.06 | Piotroski Score | 4 |
Avadel Pharmaceuticals plc (AVDL) valuation & financials
Avadel Pharmaceuticals plc (AVDL) has a market capitalization of $2.12B and trades at a price-to-earnings ratio of -1082.0. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Avadel Pharmaceuticals plc's revenue grew +79.9% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)